Sustainability is the investment for the future and it is at the core of our business.
Jubilant Life Sciences believes that addressing the challenges of the future rests
on the Triple bottom line of Sustainability.

“We have started the year on a strong note, with Pharmaceuticals business reporting healthy growth and margins. We have witnessed recovery in US Solid Dosage Formulations and also continue to see robust growth in our Specialty Pharmaceuticals business. Revenue growth in Life Science Ingredients has been led by higher volumes. We have laid the foundation for improved utilization of assets and financial discipline, leading to strengthening our balance sheet.”

Started I-131 MIBG OPTIMUM Phase II Trials in July 2018 with two sites initiated

The information collected from this study to be submitted to the USFDA under the Orphan Drug Designation program for Jubilant's NDA filing

Eligible for accelerated approval if the clinical trials are successful

Jubilant's MIBG has already been used for over a decade in USFDA approved expanded access trials and two Pediatric Oncology academic consortiums - NANT (New Approaches to Neuroblastoma Therapy) and COG (Children's Oncology Group)

Rubyfill installations in the US market progressing as per plan

Capacity addition underway at Roorkee for Generics as per plan

Portfolio of R&D products – Filings and Approvals

The Company has a total of 976 filings across geographies including 898 filings in Dosage (Orals) and 78 filings in Sterile products including JDI. Of this, 655 Dosage (Orals) and 71 Sterile Products have been approved while 250 filings (243 Dosage (Orals) and 7 sterile products) are pending approval.

On track for 6 new product launches in FY19; Commercialized one product and expect to commercialize the balance during the quarter

Life Science Chemicals:

New Acetic Anhydride plant is progressing as per plan to be commissioned by end Q3'FY19. This will provide additional revenues of Rs. 300 Crore per annum at full capacity

Favorable prices maintained during the quarter as compared to Q1'FY18

4th largest Ethanol supplier in the government blending program. Government of India has decided to raise the price of Ethanol for blending program by Rs. 2.85 per litre; applicable for supply starting from December 1, 2018

Nutritional Products:

Non-availability of Vitamin A & Vitamin E led to commensurate lower demand of Vitamin B in Feed applications leading to higher inventory and lower prices

Others Segment Review

Q1’FY19

Revenues at Rs. 51 Crore, Contributes 2% to total revenues

International markets share stood at Rs. 43 Crore, 86% of Business revenues

Revenues from North America stood at Rs. 30 Crore, contributing 59% to Business revenues

Europe and Japan business was at Rs. 10 Crore, contributing 19% to Business revenues

Corporate Announcement

In our press release dated May 23, 2017, we had informed that Jubilant Pharma Limited (“JPL”), Singapore, a wholly-owned material subsidiary of the Company, in its board meeting had resolved that it will evaluate the option of fund raising by way of an Initial Public Offering (“IPO”) by listing of its equity shares on an international stock exchange, including the Singapore Exchange, in the financial year 2018 with a dilution of not more than 15% of the issued and paid-up equity share capital of JPL. We wish to now inform you that:

1. The board of directors of the Company has taken on record the resolution dated July 23, 2018 passed by the board of directors of JPL recording that the aforementioned evaluation process is on-going and that any fund raising which may be undertaken by JPL will be by way of an IPO and that the maximum dilution of the Company’s shareholding in JPL in the IPO (including any sale of shares of JPL by the Company) will be up to 20% of the fully diluted issued and paid-up equity share capital of JPL.

2. The board of directors of the Company approved that, should an opportunity be provided to the Company in any fund raising by JPL, the Company may offer up to 5% of the ordinary equity share capital of JPL for sale.

Outlook

We expect to deliver higher revenues and operating profits in FY19. The growth drivers for each of the business are expected to be as follows:

Specialty Pharmaceuticals:

New products and current contract execution in Radiopharmaceuticals is expected to drive growth

Addition of new capacities to meet existing strong demand is expected to drive growth in CMO

Allergy Therapy Products to witness higher sales due to existing products like Venom and new capacities

API & Generics: Growth to be driven by higher volumes from new product launches and market expansions and also from initiatives to optimize costs from higher efficiencies

Life Science Ingredients: Current momentum in revenue growth expected to continue backed by healthy demand; Growth in revenues from new product launches, new orders, new capacities coming on stream and debottlenecking of existing plants

As mentioned earlier, to meet the increased demand in our businesses, we plan to invest about Rs. 550 Crores in capital expenditure and Rs. 300 Crore in R&D during the year. We will continue our efforts to strengthen balance sheet by reducing debt and improving financial ratios.

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and other businesses including Drug Discovery Solutions. The Pharmaceuticals business, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients business, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions business, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 7,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info:
www.jubl.com.